Navigation Links
Breastfeeding, other factors may affect risk of breast cancer type
Date:8/25/2008

Factors such as age at menopause as well as a woman's breastfeeding practices can influence her risk of developing certain types of breast cancer. That was the conclusion of a new study published in the October 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The study's results suggest that there are distinct and separate hormonal risk factors associated with different subtypes of breast cancer.

Clinical differences among breast cancer subtypes have been well-described, but researchers have limited data on how the various subtypes arise and which individuals are at greatest risk. Having this information could help physicians identify which women are more likely to develop certain subtypes of breast cancer, which respond differently to different anti-cancer therapies and have very different survival rates.

Amanda Phipps, a predoctoral research associate at the Fred Hutchinson Cancer Research Center in Seattle, and her colleagues conducted a study to better understand the specific risk factors for the subtypes of breast cancer, which are classified by expression of the estrogen receptor, the progesterone receptor, and the HER2 receptor. Some breast cancer types express one or more of these proteins on their cell surface, while others express none. The research team suspected that reproductive or hormonal factors may play a significant role in a woman's risk of developing different subtypes because these cell receptors are influenced by endogenous sex hormones.

For their study, the scientists pooled two population-based studies of breast cancer in women aged 55-79 years. Their analysis included 1,023 women with breast cancer whose cells express the estrogen and progesterone receptors (called luminal cancers), 39 women with HER2-overexpressing breast cancer, and 78 triple-negative cases (no expression of estrogen, progesterone, or HER2 receptors). The study also included 1,476 women without breast cancer.

The investigators found that reproductive risk factors varied considerably by breast cancer subtype. For example, early age at menarche was associated with risk of HER2-overexpressing disease but not with any other subtype. Breastfeeding for 6 months or longer was associated with a lower risk of luminal cancer as well as triple-negative cancer, a type that can be particularly aggressive and difficult to treat. Both late age at menopause and use of estrogen plus progestin hormone therapy were associated with an increased risk of luminal disease. Finally, no differences in risks associated with number of children or the age when a woman first gave birth were observed by subtype.

The study authors concluded that their results indicate that "certain reproductive factors may have a greater impact on risk of certain molecular subtypes of disease compared to others." They added that additional studies on the causes of breast cancer subtypes are needed to better understand the biology of the disease.


'/>"/>

Contact: David Sampson
david.sampson@cancer.org
American Cancer Society
Source:Eurekalert

Related medicine news :

1. More girls than boys benefit from breastfeeding, Hopkins Childrens research shows
2. Another Reason Not to Smoke While Pregnant: Birth Defects
3. FDA Warns of Codeine Risk for Some Nursing Mothers
4. More than two-thirds of sexually active NYC youth use condoms, but other forms of birth control lag
5. One Species Genome Found Within Another
6. Claim Filed Against the Company and Nine Other Defendants in the Haifa Magistrates Court
7. Family-based treatment more effective than supportive psychotherapy in treating bulimia
8. Mother and Daughter Create Lead-Free/Safe Bibs and Solve Messy Mealtime Problems
9. Mothers Know Best: NFL Moms Team With Eddie George to Showcase a Better Way to a Healthier Lifestyle
10. Eat Seafood, See Weight Loss: Recent Study Finds Another Reason to Eat Seafood for a Fit Lifestyle
11. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is ... 11th, 2016 in honor of his birthday on February 10th. During this time, ... Trivedi is known by over 250,000 people from over 40 different countries as an ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
(Date:2/7/2016)... Birmingham, Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, ... ... women on Friday in recognition of National Wear Red Day. National Wear Red ... heart disease and stroke in women. Heart disease and stroke cause 1 in 3 ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... 2016 , ... US Sports Camps is proud to sponsor the Bay Area ... top non-profit leaders, ultimate organizations, and coaches from around the US. The theme for ... Program Director of Youth and Education, describes this year YUCC as “an important conversation ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016 ... the addition of the "Label-Free Detection ... Forecasts to 2020" report to their ... announced the addition of the "Label-Free ... Global Forecasts to 2020" report to ...
(Date:2/8/2016)... , Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced that it will ... ended December 31, 2015 after market close on February 9, ... conference call to discuss these financial results.    ... --> About Unilife Corporation ...
(Date:2/8/2016)... 8, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... announced that the U.S. Food and Drug Administration ... (IND) application for SB-318, a single treatment strategy ... Type I (MPS I). The SB-318 IND application ... a Phase 1/2 clinical study (SB-318-1502) designed to ...
Breaking Medicine Technology: